Ieq Capital LLC Buys 45,424 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Ieq Capital LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 557,904 shares of the company’s stock after acquiring an additional 45,424 shares during the quarter. Neurocrine Biosciences comprises approximately 0.7% of Ieq Capital LLC’s holdings, making the stock its 23rd largest holding. Ieq Capital LLC owned 0.55% of Neurocrine Biosciences worth $76,154,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Peregrine Capital Management LLC increased its position in Neurocrine Biosciences by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 64,840 shares of the company’s stock worth $8,851,000 after acquiring an additional 1,159 shares during the period. CIBC Asset Management Inc increased its position in Neurocrine Biosciences by 13.6% during the fourth quarter. CIBC Asset Management Inc now owns 4,078 shares of the company’s stock worth $557,000 after acquiring an additional 487 shares during the period. Sanctuary Advisors LLC increased its position in Neurocrine Biosciences by 7.1% during the fourth quarter. Sanctuary Advisors LLC now owns 8,191 shares of the company’s stock worth $1,118,000 after acquiring an additional 542 shares during the period. Capital Performance Advisors LLP increased its position in Neurocrine Biosciences by 1,101.4% during the fourth quarter. Capital Performance Advisors LLP now owns 1,730 shares of the company’s stock worth $236,000 after acquiring an additional 1,586 shares during the period. Finally, Sheaff Brock Investment Advisors LLC increased its position in Neurocrine Biosciences by 11.7% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 2,499 shares of the company’s stock worth $341,000 after acquiring an additional 261 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 0.3 %

Shares of NASDAQ NBIX opened at $114.26 on Thursday. The firm has a market capitalization of $11.39 billion, a PE ratio of 34.73, a price-to-earnings-growth ratio of 0.78 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The firm’s 50-day moving average is $136.97 and its 200-day moving average is $129.81.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NBIX has been the topic of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Guggenheim dropped their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a research note on Monday, February 10th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Morgan Stanley increased their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, Wedbush dropped their price objective on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $166.90.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at approximately $338,445. This trade represents a 30.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kevin Charles Gorman sold 146,105 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the sale, the director now owns 514,596 shares in the company, valued at $76,911,518.16. This trade represents a 22.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 236,600 shares of company stock worth $34,348,261 in the last ninety days. Company insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.